Paushak

₹5200 20.9 | 0.4%

WEBSITE BSE:532742 NSE : PAUSHAKLTD 10 May, 16:01

Market Cap ₹1603 Cr.

Stock P/E 29.5

P/B 5

Current Price ₹5200

Book Value ₹ 1037.3

Face Value 10

52W High ₹7425

Dividend Yield 0.38%

52W Low ₹ 4464

Edit Ratio

Paushak Research see more...

Overview Inc. Year: 1972Industry: Chemicals

Paushak Ltd is an totally India-based pharmaceutical organisation, that's engaged within the development and production of phosgene-primarily based chemical compounds and intermediates. The Company is engaged within the production of organic intermediates products, such as Isocyanates, which encompass 2-Phenyl Ethyl Isocyanate, 2- Cyclohexyl Isocyanate and Cyclohexyl Isocyanate; Chloroformates, which comprises 2- Ethylhexyl Chloroformate, n-Hexyl Chloroformate, Isobutyl Chloroformate and Para Nitrophenyl Chloroformate; Carbamoyl Chlorides, which consist of Diethylcarbamoyl Chloride, Diphenylcarbamoyl Chloride and N-Ethyl-N-Methylcarbamoyl Chloride, and Others, which consist of 3,4,4-Trichlorocarbanilide, Chloromethyl Isopropyl Carbonate and 4,5-Dimethyl-1, 3-Dioxolen-2-One. Its merchandise under development comprises 2-Phenoxyethyl Chloroformate, Cetyl Chloroformate, Tert-Butyl Cyclohexyl Chloroformate, 4-Chloromethyl-5methyl-1,3-dioxol-2-one, Isopropyl chloroformate, Menthyl Chloroformate and others.

Paushak Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Paushak Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	34	53	50	50	56	56	49	52	52	54
Other Income	0	1	1	5	1	2	4	7	3	7
Total Income	34	53	51	54	57	59	52	59	55	61
Total Expenditure	22	32	32	33	35	37	36	38	33	35
Operating Profit	12	21	19	21	22	22	16	21	22	26
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	3	3	3	3	3	3	3	3	3	4
Exceptional Income / Expenses	0	0	0	0	2	0	0	0	0	0
Profit Before Tax	9	18	16	18	20	19	12	18	18	23
Provision for Tax	2	5	4	5	5	4	3	4	5	4
Profit After Tax	7	13	12	13	15	14	9	13	14	18
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	7	13	12	13	15	14	9	13	14	18
Adjusted Earnings Per Share	23.3	42.9	37.5	42.5	48.8	46.6	29.7	43.3	44.3	59.3

Paushak Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	51	56	69	78	67	103	140	138	141	150	212	207
Other Income	1	2	3	3	5	3	3	5	6	5	9	21
Total Income	52	58	72	81	72	106	142	143	147	155	221	227
Total Expenditure	39	43	52	61	55	74	99	95	91	96	137	142
Operating Profit	13	15	20	19	17	32	43	47	57	59	84	85
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2	2	2	3	3	3	4	4	5	9	13	13
Exceptional Income / Expenses	0	0	0	0	0	0	10	2	0	0	2	0
Profit Before Tax	11	13	18	17	14	29	49	45	52	50	72	71
Provision for Tax	3	4	5	4	3	7	10	10	14	13	18	16
Profit After Tax	8	9	13	12	11	21	39	35	37	38	54	54
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	8	9	13	12	11	21	39	35	37	38	54	54
Adjusted Earnings Per Share	24.3	27.5	40.5	38.7	34.1	66.9	126.4	113.3	121	122	175.2	176.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	41%	15%	16%	15%
Operating Profit CAGR	42%	21%	21%	21%
PAT CAGR	42%	16%	21%	21%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-26%	-11%	18%	44%
ROE Average	16%	15%	18%	19%
ROCE Average	22%	20%	23%	26%

Paushak Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	38	46	57	69	83	113	178	227	272	306	354
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1	1	2	2	4	9	22	26	30	34	39
Total Current Liabilities	15	19	9	11	7	22	15	16	27	27	22
Total Liabilities	55	65	69	82	94	144	214	270	329	367	415
Fixed Assets	10	9	18	20	35	37	38	41	51	147	149
Other Non-Current Assets	13	13	12	22	33	52	86	119	183	116	119
Total Current Assets	32	43	38	40	26	56	90	111	95	104	147
Total Assets	55	65	69	82	94	144	214	270	329	367	415

Paushak Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	0	0	0	0	0	0	1	1	0	0
Cash Flow from Operating Activities	3	9	9	14	12	10	24	45	30	44	43
Cash Flow from Investing Activities	0	-7	-8	-13	-11	-10	-0	-43	-29	-42	-38
Cash Flow from Financing Activities	-3	-2	-1	-1	-2	-1	-23	-2	-2	-2	-4
Net Cash Inflow / Outflow	0	0	0	0	-0	0	0	0	-1	-0	0
Closing Cash & Cash Equivalent	0	0	0	0	0	0	1	1	0	0	1

Paushak Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	24.3	27.5	40.52	38.72	34.12	66.95	126.4	113.27	121.02	122.03	175.22
CEPS(Rs)	29.91	33.07	47.18	47.46	44.14	77.51	138.94	127.49	137.11	151.32	218.76
DPS(Rs)	3	3	3	3	3	3	5	6	6	12	17.5
Book NAV/Share(Rs)	118.39	142.41	178.96	214.07	258.86	352.75	576.12	737.3	881.43	991.41	1147.57
Core EBITDA Margin(%)	21.3	21.26	23.59	20.02	16.75	28.02	28.81	31.01	35.79	36.13	35.41
EBIT Margin(%)	20.12	21.09	24.32	19.91	19.6	27.65	35.21	32.96	36.62	33.54	34.16
Pre Tax Margin(%)	19.77	20.88	24.27	19.84	19.52	27.56	35.12	32.9	36.59	33.5	34.01
PAT Margin (%)	14.36	14.6	17.53	14.83	15.13	20.5	27.93	25.32	26.45	25.06	25.43
Cash Profit Margin (%)	17.67	17.55	20.42	18.18	19.57	23.73	30.7	28.49	29.97	31.07	31.75
ROA(%)	15.28	14.68	19.41	16.52	12.43	17.99	21.73	14.43	12.46	10.82	13.83
ROE(%)	22.51	21.09	25.21	19.7	14.43	21.89	26.8	17.25	14.95	13.03	16.38
ROCE(%)	29.81	30.05	34.89	26.29	18.63	29.44	33.73	22.45	20.7	17.44	22
Receivable days	72.55	85.85	88.11	92.19	93.68	95.95	93.12	77.61	76.49	88.33	79.25
Inventory Days	51.58	46.49	36.11	35.28	44.71	36.03	39.24	45.2	38.88	39.84	35.85
Payable days	78.66	71.49	78.5	96.33	94.23	108.65	95.87	98.56	132.67	181.06	134.15
PER(x)	2.74	5.69	9.04	15.28	16.97	19.22	16.04	15.27	69.06	85.18	35.48
Price/Book(x)	0.56	1.1	2.05	2.76	2.24	3.65	3.52	2.35	9.48	10.48	5.42
Dividend Yield(%)	4.51	1.92	0.82	0.51	0.52	0.23	0.25	0.35	0.07	0.12	0.28
EV/Net Sales(x)	0.44	0.89	1.7	2.44	2.78	3.99	4.47	3.86	18.26	21.34	9.02
EV/Core EBITDA(x)	1.75	3.44	5.82	9.75	10.66	12.76	14.57	11.22	45.5	53.96	22.73
Net Sales Growth(%)	51.26	10.85	22.47	12.91	-14.42	55.14	34.89	-1.15	2.24	6.45	41.47
EBIT Growth(%)	145.93	16.68	41.45	-7.52	-14.96	104.3	69.61	-7.48	13.61	-2.52	44.09
PAT Growth(%)	126.09	13.17	47.31	-4.43	-11.88	96.22	81.44	-10.38	6.83	0.84	43.59
EPS Growth(%)	126.09	13.17	47.31	-4.43	-11.88	96.22	88.8	-10.38	6.83	0.84	43.59
Debt/Equity(x)	0.03	0	0	0.01	0	0.01	0	0	0	0	0
Current Ratio(x)	2.05	2.34	4.08	3.61	3.69	2.49	6.07	6.81	3.49	3.83	6.6
Quick Ratio(x)	1.55	1.93	3.33	2.78	2.48	1.95	4.86	5.81	2.98	3.13	5.58
Interest Cover(x)	57.31	102.73	461.03	276.45	239.88	295.24	360.16	592.57	1051.69	818.52	233.23
Total Debt/Mcap(x)	0.05	0	0	0	0	0	0	0	0	0	0

Paushak Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	66.97	66.97	66.97	66.97	66.97	66.97	66.97	66.97	66.97	66.97
FII	0	0	0	0	0.01	0.01	0.02	0.02	0.02	0.02
DII	0	0	0	0	0	0	0	0	0.11	0.2
Public	33.03	33.03	33.03	33.03	33.02	33.02	33.01	33.01	32.9	32.8
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.21
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Others	0	0	0	0	0	0	0	0	0	0
Total	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31

Pros

Debtor days have improved from 181.06 to 134.15days.
Company is almost debt free.

Cons

Stock is trading at 5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.